FindTrial
Sign In

Placebo (for teriflunomide)

DRUG5 trials

Sponsors

Sanofi

Conditions

Multiple SclerosisMultiple Sclerosis Relapse

Phase 2

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
CompletedNCT00475865
SanofiMultiple Sclerosis
Start: 2007-04-30End: 2009-10-31Updated: 2012-11-06
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
CompletedNCT00489489
SanofiMultiple Sclerosis
Start: 2007-05-31End: 2009-06-30Updated: 2012-11-06
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
CompletedNCT00811395
SanofiMultiple Sclerosis
Start: 2007-10-31End: 2010-04-30Updated: 2012-12-31

Phase 3

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
CompletedNCT00134563
SanofiMultiple Sclerosis
Start: 2004-09-30End: 2010-07-31Updated: 2013-01-04
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
TerminatedNCT01252355
SanofiMultiple Sclerosis Relapse
Start: 2011-01-31End: 2013-04-30Updated: 2014-06-09

Related Papers

Exploring New Imaging Biomarkers: 3D Conformational Analysis Of The Medulla And Upper Cervical Spinal Cord In People With Relapsing Multiple Sclerosis (P11-3.015)
Neurology2023-04-25
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
Multiple Sclerosis Journal2022-04-2911 citations
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
2020-10-062 citations
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
Multiple Sclerosis Journal2019-06-1433 citations
Brain Volume Loss and Cognition in Teriflunomide-Treated Patients in TEMSO (P5.2-058)
Neurology2019-04-091 citations
068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study
Journal of Neurology Neurosurgery & Psychiatry2018-05-246 citations
066 Impact of long-term teriflunomide treatment on lymphocyte counts and infections in pooled temso and tower studies
Journal of Neurology Neurosurgery & Psychiatry2018-05-24
Evaluation of the Long-term Treatment Effect of Teriflunomide on Cognitive Outcomes and Association With Brain Volume Change: Data From TEMSO and its Extension Study (P6.372)
Neurology2018-04-101 citations
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
Multiple Sclerosis Journal - Experimental Translational and Clinical2018-04-015 citations
Drug repurposing for neuroregeneration in multiple sclerosis
Neural Regeneration Research2018-01-0110 citations
Teriflunomide slows BVL in relapsing MS
Neurology Neuroimmunology & Neuroinflammation2017-08-1068 citations
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
Neurology Neuroimmunology & Neuroinflammation2017-06-2921 citations
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
Multiple Sclerosis Journal2017-03-1718 citations
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
2016-11-0326 citations
Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038)
Neurology2016-04-054 citations
Teriflunomide Significantly Slows Brain Volume Loss in MS Patients Irrespective of Disability Progression (P3.047)
Neurology2016-04-053 citations
Teriflunomide Slows Brain Volume Loss in Relapsing MS: A SIENA Analysis of the TEMSO MRI Dataset (P3.089)
Neurology2016-04-053 citations
Teriflunomide Slows Brain Volume Loss: Subgroup Analysis of the SIENA TEMSO MRI Dataset (P3.052)
Neurology2016-04-052 citations
Number Needed to Treat Analysis Comparing Teriflunomide and Injectable Disease-Modifying Therapies (P6.173)
Neurology2016-04-051 citations
Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score (P2.108)
Neurology2016-04-05

18 more papers not shown